Tag Archives: business

Beyond Borders: How to Prepare for Partnering Success at RESI London in the “Winter” 

4 Nov

By Greg Mannix, VP, EMEA Business Development, LSN

When was the last time you spoke directly with an investor? Or better yet how often do you have the chance to meet with multiple qualified investors in a single day? 

In today’s challenging investment climate, life science startups can’t afford to slow down their fundraising efforts. Capital is still out there, but it requires thinking beyond borders. 

To thrive in this “winter,” fundraising CEOs must: 

  • Step outside their regional ecosystems 
  • Build global visibility 
  • Connect directly with investors, in-licensors, and strategic partners who are still actively deploying capital 

That is exactly what RESI London 2025 is designed to help you do. 

Why Partnering Conferences Matter 

Partnering conferences, like RESI, give startups a fast, efficient way to meet investors who are aligned with their technology, stage, and strategy. Instead of spending months chasing introductions, companies can meet dozens of potential partners across two or three days. These concentrated interactions save time, reduce travel costs, and dramatically increase fundraising success rates. 

How to Prepare for a Partnering Conference 

Preparation determines success. Before meetings begin, make sure your company profile, pitch deck, and meeting strategy are ready. 

Join Life Science Nation’s free Partnering Tutorial Webinar on Monday, November 10 at 10 AM Eastern to learn how to navigate the RESI Partnering Platform, refine your outreach, and get ready to meet investors. 

Sign Up Free Webinar

RESI’s Unique Approach to Partnering 

Unlike most conferences, which offer only basic scheduling tools, the RESI Partnering Platform is built specifically for early-stage life sciences. It features a curated database of investor profiles gathered through direct interviews. Startups can filter investors by type, indication, and development stage to find their most relevant matches. This data-driven approach makes your meetings more targeted and impactful. 

RESI Survival Guide 

To help fundraising executives make the most of RESI, LSN developed the RESI Survival Guide, outlining five essential steps to partnering success. It covers how to identify the right investors, structure your day, and follow up effectively after the event. 

Ways to Partner: Standard vs. Premier Access 

Premier Access attendees enjoy additional benefits, including early access to investor profiles, enhanced visibility, and dedicated support from the LSN team. Whether you choose Standard or Premier, every investor profile on the RESI platform is verified and interviewed to ensure a high-quality partnering experience. 

Register for RESI London Appy to Pitch at RESI London

Tags: , , , , ,

Hot Investor Mandate: VC Firm Headquartered in Asia Seeks Early-Stage Life Science Companies in the Intersection of Science and Technology

4 Nov

 
This venture capital firm focuses on breakthrough technologies transforming healthcare and typically invests at the pre-seed, seed, and pre-Series A stages. The firm is backed by limited partners from within the healthcare industry, reinforcing its domain expertise and strategic alignment with clinical innovation. 

The firm targets early-stage life science startups working at the intersection of cutting-edge science and healthcare applications. Areas of interest include genomic technologies, synthetic biology, digital health, machine learning and artificial intelligence, therapeutics, and diagnostics. In therapeutics, the firm focuses on pre-IND assets, while for technologies regulated as medical devices, the firm prioritizes smart devices at the pre-commercial stage. 

With a team that brings a strong clinical perspective, the firm actively supports its portfolio companies through clinical development and has a history of helping academic scientists translate research into commercial ventures. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Private Investment Firm Invests in Seed to Series A Medical Devices, Diagnostics, and Digital Health Companies in North America

4 Nov

An investment firm headquartered in the US focuses on healthcare companies across the seed, venture, and growth stages. The firm typically provides seed and Series A equity financing ranging from $100K to $1M per portfolio company. While the firm often acts as a lead investor, it is also open to participating in syndicated rounds. The firm is open to investment opportunities throughout North America. The firm is actively seeking new investments. 

Current areas of interest include medical devices, diagnostics, digital health, and healthcare-focused software. The firm is also open to reformulated or repurposed drugs, particularly those with reduced development risk. In the medical device category, the firm remains opportunistic across subsectors, with a preference for products that have a prototype and follow the 510(k) regulatory pathway. The firm is indication-agnostic, with interest that includes orphan diseases and the dental field. 

The firm places a strong emphasis on working with experienced management teams and may take a board seat when appropriate. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Europe-Based VC Firm Invests in Early-Stage Companies in Tech-Enabled Life Science and Healthcare Companies

4 Nov

 
This growth-focused investment firm is headquartered in Europe, and was founded by entrepreneurs who previously built and exited a unicorn multinational company. With a renewed mission to drive innovation and growth, the firm targets both early-stage life science ventures and established professional service providers. 

In the early-stage segment, the firm typically invests up to €500K in Series A rounds and makes smaller allocations at the Seed stage. The investment strategy centers on innovative, tech-enabled, and service-oriented companies within the life sciences and healthcare sectors. While the firm is open to early-stage opportunities, it prefers companies with a proven business model and a clear path to scale. 

The firm is eager to partner with strong management teams developing solutions that address unmet needs with a compelling value proposition. Most investments are made as part of a syndicate with institutional venture capital firms, and the firm contributes beyond capital by offering deep sector expertise, an extensive network, and a strong entrepreneurial track record. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Western Europe-Based Firm Invests Up to $10M in Life Sciences Including Drug Discovery and Enabling Technologies

4 Nov

This Western Europe-based investment firm has been active for over two decades and manages multi-billion in assets under management. The firm takes a sector-agnostic approach, investing across a broad spectrum including enterprise software, fintech, consumer technologies, deeptech, and life sciences. 

Typical equity investments range from $1 million to $10 million, and the firm expects to make several new investments annually. While companies must maintain a local operational presence in the firm’s home country, they may also have international footprints. 

In the life sciences and biotech space, the firm adopts a wide-angle lens, looking for companies developing drug discovery platforms, synthetic biology innovations, and enabling research technologies.  

The firm is open to investing in pre-revenue companies, and is supportive of both emerging and experienced founding teams. It frequently invests at the early growth stage, often in syndicate with other institutional investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

ApexBrasil and ABIQUIFI Deepen Strategic Alliance with Life Science Nation to Globalize Brazil’s Life Science Ecosystem and Leveraging the RESI JPM January Event 

28 Oct

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

São Paulo – Boston | October 2025

Brazil is taking a significant step toward global integration in the life sciences. Last week, ApexBrasil (the Brazilian Trade and Investment Promotion Agency) and ABIQUIFI (the Brazilian Association of Pharmaceutical Inputs Industry) hosted Life Science Nation (LSN) and Ganesha Labs in São Paulo for a week of meetings, workshops, and strategic dialogues with key stakeholders from across the national innovation and investment landscape. 

The visit culminated during the Corporate Venture in Brasil 2025 Conference, held in São Paulo and co-hosted by ApexBrasil, which gathered leading investors, corporate venture leaders, development agencies, and innovation stakeholders to strengthen Brazil’s position in the global market. 

At the conference, LSN’s CEO, Dennis Ford, delivered a masterclass on running global fundraising campaigns and building two-way innovation bridges between regional science and global capital. This was followed by a panel discussion, “Where Brazil Is and Where We Should Aim Towards,” featuring KX Ventures, IKJ, Sebrae, Ganesha Labs, and Life Science Nation, and moderated by Marcos Valadares of ABIQUIFI. 

Over several days surrounding the conference, ApexBrasil and ABIQUIFI facilitated a series of high-level introductions that connected LSN and Ganesha Labs with leaders from accelerators, investment groups, and research institutions across Brazil. These discussions focused on aligning Brazil’s growing innovation infrastructure with global commercialization frameworks and investor networks. 

The São Paulo visit capped two years of collaboration between the organizations, during which ApexBrasil and ABIQUIFI have sent multiple cohorts of Brazilian life-science companies to LSN’s Redefining Every Stage of Investment JPM events and LSN Labs training programs. 

Together, they have provided Brazilian entrepreneurs with a structured path to international investors and licensing partners, and a deeper understanding of how to prepare and execute a global fundraising campaign. 

This ongoing collaboration is laying the groundwork for Brazil to become a formal anchor node in the LSN Global Partnering Ecosystem. This worldwide network links regional innovation hubs to global capital and corporate partners. Through continued coordination, the parties aim to establish a lasting two-way innovation bridge between Brazil and LSN’s international ecosystem, enabling Brazilian technologies to access global markets while channeling international investors and strategic partners into the country’s rapidly expanding life-science sector. 

According to Dennis Ford, Founder and CEO of Life Science Nation, 

“Brazil’s scientific depth and entrepreneurial momentum make it one of the most exciting emerging markets in life sciences. ApexBrasil and ABIQUIFI are doing exactly what global investors want to see—creating a coordinated pathway that connects local innovation with international capital and commercialization opportunities. LSN is proud to help Brazil take this next step.” 

Norberto Prestes, CEO of ABIQUIFI, emphasized the export and funding side of the bridge: 

“Brazil has a rich foundation of science and talent. Our goal is to help these innovations secure the visibility, funding, and partnerships they need to reach international markets. The collaboration with LSN provides the structure and access needed to make that happen.” 

Debora Lima of ApexBrasil highlighted the importance of bringing international investors into the Brazilian ecosystem: 

“Our mission is to connect Brazil with the world—to bring investors, partners, and collaborators to see firsthand the innovation emerging here. Working with LSN allows us to open new channels for global capital to engage directly with Brazilian startups and research institutions.” 

About Life Science Nation

Life Science Nation (LSN) is a global matching and partnering engine that connects early-stage life-science companies with investors and licensing partners through its integrated ecosystem—including the LSN Investor & Licensing Partner Database, the RESI Conference Series, and LSN Labs Accelerator. LSN has supported more than 400 companies in raising over $5 billion in verified funding worldwide.

About ApexBrasil

ApexBrasil promotes Brazilian products and services abroad and attracts foreign investment to strategic sectors of the Brazilian economy, strengthening national competitiveness and international presence.

About ABIQUIFI

ABIQUIFI represents the Brazilian Pharmaceutical Inputs Industry, advancing innovation, quality, and competitiveness across the national health and life-sciences sector.

Registration now open:

  • RESI London 2025 (Dec. 4, 8&9) – [Register]
  • RESI JPM 2026 (Jan.12-14, 19&20)– [Register]
  • RESI Europe 2026 (March 23-25) – [Register]

Tags: , , , , , , , , , , ,

RESI London 2025: An International Hub for Connections 

28 Oct

By Greg Mannix, VP, EMEA Business Development, LSN

The Redefining Every Stage of Investment (RESI) Conference is coming back to London on December 4th — and it’s shaping up to be bigger and better than ever. After a successful debut in 2024, RESI London returns to unite global investors, strategic partners, and early-stage innovators across biotech, medtech, diagnostics, and digital health. 

In today’s challenging funding landscape, breaking out of your regional bubble to build global relationships is essential. That’s exactly what RESI delivers — a trusted international platform where meaningful connections spark real partnerships and deals. 

With 54 conferences held across three continents since 2012, RESI has become a cornerstone of the global life science community, helping startups find the right investors, and investors find their next breakthrough. 

This December, RESI London will welcome international Tech Hubs and Regional Organizations collaborating through startup cohorts, promotional activities, and partner initiatives. 

We’re excited to welcome cohorts from:

  • Ontario (Canada)
  • CEIN Navarra (Spain) 
  • OneNucleus (UK) 

And we’re grateful for the ongoing collaboration of our global partners, including:
BioPartner UK, O2h (UK), Genopole, Lyonbiopole & Eurasanté (France), Life Science Zurich BP (Switzerland), BioM & BioRN (Germany), Biocat & Asebio (Spain), BioIndustry Park (Italy), PBio (Portugal), Business Regions Gotheborg/Skane (Sweden) — and many more. 

Join us in London on December 4th to connect with the global life science ecosystem and take your innovation to the next level. There is still time to pitch in the Innovator’s Pitch Challenge APPLY HERE 

90 companies have documented raising $1.29 B from connections started at RESI. Read More. 

Register for RESI London Appy to Pitch at RESI London

Tags: , , , ,

← Older Entries
Newer Entries →